BioCryst (BCRX) wins Japan approval for ORLADEYO® pediatric HAE patients
BioCryst announces approval of ORLADEYO® for pediatric HAE patients in Japan, expanding the company’s approved use in that market.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.